Medically reviewed by Jurairat J. Molina, MD Dermatitis is a group of skin problems related to genes, environment, and ...

Amesanar is under clinical development by RHEACELL and currently in Phase II for Diabetic Foot Ulcers. According to GlobalData, Phase II drugs for Diabetic Foot Ulcers does not have sufficient ...

Sulodexide is under clinical development by Alfasigma and currently in Phase III for Venous Thromboembolism. According to GlobalData, Phase III drugs for Venous Thromboembolism have a 60% phase ...

Non-healing wounds may signal gangrene, a severe condition caused by tissue death due to poor oxygen and blood flow. Early ...

The event will focus on EscharEx, an innovative biologic drug in late-stage development for chronic wound debridement, specifically targeting Venous Leg Ulcers (VLUs). The event will feature three ...

Treatment is aimed at ... apparatus can lead to venous stasis and elevated pressures. Shown are lipodermatosclerosis, corona phlebectatica, venous leg ulcer, and pes planus (Panel A); swelling ...

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment ... venous CVI." Severe, deep venous Chronic Venous Insufficiency ...

trial in patients with severe chronic venous insufficiency. The current treatment modalities for venous ulcers include conservative management, mechanical modalities, medications, advanced wound ...

The biologic therapy, injected below the skin, is being developed to promote healing of venous leg ulcers (VLUs ... first biologic drug therapy for the treatment of VLUs that pose a significant ...

Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers ... the treatment of deep venous Chronic Venous Insufficiency ...